The present invention relates to novel alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines,
to intermediates and methods for their preparation, to pharmaceutical compositions
containing them and to their medicinal use. The compounds of the present invention
are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in
the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion
or ischemia in stroke or heart attack, autoimmune diseases and other disorders.